Interim report
Page 1
1 IMPLANTICA INTERIM REPORT Q2-261 Interim Report Financial Summary Figures within parentheses refer to the preceding year. Second Quarter • Net sales increased by 66% to TEUR 717 (433). • Adjusted gross margin amounted to 94% (90%). • Operating loss (EBIT) decreased to TEUR 4,200 (4,525). • Loss after tax amounted to TEUR 3,987 (5,448). • Basic and diluted loss per Class A share amounted to EUR 0.06 (0.08). • Cash and cash equivalents as at the end of the period of MEUR 41.7. Significant Events • RefluxStop® sales increased by more than 60% compared with the prior-year period, reflecting continued commercial growth across key European markets • Largest independent RefluxStop® study to date published in Nature’s Scientific Reports, reporting mid- to long-term safety outcomes in 602 patients across 22 centers in six European countries, with serious safety events and reoperations below 2% • Clinical, health-economic and reimbursement evidence further strengthened, including new Italian cost-effectiveness data and the addition of a seventh InEK-reporting hospital in Germany supporting the reimbursement pathway • FDA PMA approval secured for RefluxStop®, opening the U.S. market and enabling the start of U.S. commercial launch activities • U.S. market entry underway, with expansion of the U.S. organization and establishment of logistics and distribution infrastructure • European market presence continued to expand, including the 20th Center of Excellence in Spain at MD Anderson Madrid and new Centers in Switzerland and the UK, bringing the European network to more than 60 Centers of Excellence IN THE SECOND QUARTER OF 2026 AFTER THE END OF THE PERIOD JUNE 2026JANUARYQ2 • Net sales increased 34% to TEUR 1,574 (1,178). • Adjusted gross margin amounted to 94% (94%). • Operating loss (EBIT) decreased to TEUR 8,058 (8,698). • Loss after tax amounted to TEUR 8,267 (8,212). • Basic and diluted loss per Class A share amounted to EUR 0.12 (0.12). First Six Months
Page 2
2 IMPLANTICA INTERIM REPORT Q2-262 FDA Approval of RefluxStop® – Strategic Preparation Sets the Stage for Success CEO Comments DR. PETER FORSELL CEO, IMPLANTICA FDA PMA approval of RefluxStop ® marks one of the most important milestones in Implantica’s history. After years of clinical development, extensive regulatory review and preparation, we can now bring RefluxStop® to the United States and begin our commercial expansion into the world’s largest healthcare market. This is an important moment for Implantica and for the many surgeons, clinical investigators and employees who have contributed to the development of RefluxStop®. It also represents an important opportunity for the patients when our innovative treatment becomes available to the 78 million patients suffering from GERD in the United States. The approval follows an extensive FDA PMA review process, including detailed regulatory review, on-site inspections, supplementary testing and evaluation of long-term clinical data. With this process successfully completed, our focus now turns from preparation to execution. We have a detailed plan to accelerate the commercial and operational activities required to establish RefluxStop ® in the U.S. market. We are progressing the expansion of our U.S. organization with experienced personnel across sales, business development, surgical training, reimbursement and clinical development. We are also establishing the logistics and distribution infrastructure required to support commercial operations and future growth. Our commercial strategy will be targeted to initially focus on leading reflux surgeons and high-volume centers, supported by appropriate training and clinical support. Over several years, we have developed relationships with leading U.S. surgeons and experts through scientific meetings and professional engagement. FDA approval now allows us to build on these relationships as we move from scientific and clinical engagement to commercial adoption. More than 100 U.S. surgeons have already expressed interest to start with the RefluxStop ® procedure, reflecting the exceptionally strong engagement we are seeing among U.S. surgeons. Commercial adoption is expected to build gradually reflecting the physician training and site activation required to establish RefluxStop® at each center. Importantly, we enter the U.S. market with a substantial foundation already established. RefluxStop® has been used in close to 1,800 patients, with more than 60 Centers of Excellence established across nine European countries. We have published five-year clinical outcomes and RefluxStop® is now supported by more than 38 scientific publications, including growing real-world and health-economic evidence. This is a very different starting position from launching a new medical technology without established clinical or commercial experience. Years of commercialization in Europe have taught us how to establish Centers of Excellence, train surgeons, support adoption and develop the clinical and health-economic evidence needed for reimbursement and broader market access. We believe this experience, together with our existing relationships with U.S. surgeons and the mature clinical evidence available at launch, provides a strong foundation for our U.S. expansion. To summarize our launch focus will be on disciplined execution, high-quality surgeon training and establishing the clinical and commercial infrastructure required for sustainable long-term growth. Alongside this major U.S. milestone, our European business continued to develop strongly during the second quarter. RefluxStop® sales increased by more than 60% compared with the prior-year period, reflecting increasing adoption across our key markets. Health economic analysis today plays an important role in establishing new treatments. This is supported, for example, in Italy where a favorable health-economic analysis evaluating RefluxStop® within the Italian healthcare system was newly published. The RefluxStop® U.S. launch is a significant milestone, allowing us to build on the strong clinical, health-economic and reimbursement foundation established ahead of our U.S. market entry. FDA Premarket Approval (PMA) of RefluxStop ® marks a defining period for Implantica, opening the U.S. market and enabling the start of our commercial launch. We delivered more than 60% sales growth in Europe and continued to expand commercial adoption and reimbursement progress across European markets. U.S. Launch – From Preparation to Execution FDA Approval & U.S. Launch of RefluxStop® Strong Commercial Growth Continues in Europe With FDA approval secured, our focus now shifts from preparation to execution as we launch RefluxStop® in the United States.
Page 3
3 IMPLANTICA INTERIM REPORT Q2-263 The analysis showed that RefluxStop ® is substantially more cost-effective compared with PPI medical therapy, magnetic sphincter augmentation, and standard-of-care Nissen fundoplication. We have received 4 public tender wins in Italy further strengthening the economic case for RefluxStop ® as we work towards broader reimbursement and adoption. One example is the EUR 1.2 million multi-year public tender awards announced earlier this year, in total reaching EUR 2.3 million public funding in Italy, which now generate continued orders. Spain demonstrates the strong adoption potential of RefluxStop ® in markets where surgeons and patients have greater influence over treatment decisions. Despite budget constraints, the number of hospitals adopting RefluxStop ® is continuing to grow. In Spain, we have reached the 20th RefluxStop ® Center of Excellence with the addition of MD Anderson Madrid, the first international location of the world-renowned MD Anderson Cancer Center based in Houston, Texas. Key new Centers of Excellence were also established at Hirslanden Klinik Im Park in Zurich, Switzerland, and Nuffield Wessex Hospital in Southampton, UK, further expanding our presence across key European markets. Germany remains an important market for our long-term European growth strategy, with up to 12,000 surgeries performed annually to treat acid reflux. We have already achieved an important milestone by securing a dedicated OPS procedure code (the German equivalent of a medical procedure/billing code) for RefluxStop®. However, the next step is to establish appropriate reimbursement through the German healthcare body called InEK, which determines reimbursement levels based on real-world cost data reported by a select group of German hospitals. Given the limited number of InEK cost-reporting hospitals performing anti-reflux surgery, expanding our network of participating centers is critical. We are therefore pleased to announce that we have added a seventh InEK-reporting hospital performing RefluxStop® procedures, further strengthening the cost-data base required to support to finally get reimbursed for the procedure in Germany. InEK requires sufficient annual procedure volumes to conduct its cost assessment and determine an appropriate real cost reimbursement level. Building volume across our network of reporting hospitals therefore remains an important priority. Our clinical evidence base continued to strengthen during the quarter. The largest independent RefluxStop ® study to date was published in Scientific Reports, a Nature group journal . The scale and independent multicenter nature of this study are particularly important. The results reflect real-world experience across a broad group of European centers and further strengthens the evidence supporting RefluxStop ®. The multicenter study evaluated 602 patients treated at 22 centers across six European countries and demonstrated a favorable mid- to long-term safety profile, with serious safety events and reoperations occurring in less than 2% of patients, a multitude lower figure than standard of care. Together with the previously published five-year clinical outcomes, RefluxStop® is now supported by more than 38 scientific publications. We believe this clinical and health-economic evidence provides an important foundation as we introduce RefluxStop® to U.S. surgeons, hospitals and payers. While RefluxStop® remains our absolute core strategic priority, Implantica has an extensive pipeline. Our innovation platform extends into implantable eHealth and wireless energizing and com - munication platform technologies and a large number of IP covered products utilizing our new ultra-smart technology. We believe these platforms will change healthcare forever and offer substantial long-term potential across a range of therapeutic areas. This opportunity is supported by our extensive intellectual property portfolio, including more than 25,000 pages of patent filings relating to our eHealth and wireless energizing and communication platform technologies. FDA approval fundamentally changes the opportunity ahead of Implantica. After years of building the clinical, commercial and reimbursement foundation for RefluxStop ® in Europe, we can now apply that experience to the U.S. market, targeting a “splash in the U.S. market” launch, while continuing to expand our European business. I am extremely proud of what our team has accomplished in achieving FDA approval. It represents the culmination of many years of work by our employees, clinical investigators, surgeons and partners, and I would like to thank them for their extraordinary commitment throughout this journey. I would also like to thank our shareholders for their continued trust and support. FDA approval is a major achievement, but it is also the beginning. We enter this next phase with great enthusiasm and a clear focus on execution, as we work to establish RefluxStop ® as the leading treatment in the world’s largest healthcare market. Yours sincerely, Dr. med. Peter Forsell, Surgeon and Inventor CEO and Founder, Implantica Advancing Reimbursement in Germany Expanding Clinical Evidence Supports U.S. and European Growth Future Innovation and Product Pipeline A New Phase for Implantica
Page 4
IMP L A NT I CA I NT E R IM R E P O R T Q2-26 4 IMPLANTICA IN BRIEF Implantica is a MedTech group committed to providing effective care for serious health conditions and improving patient quality of life by bringing advanced technology into the body. Simultaneously, Implantica aims to reduce overall costs and improve efficiency in the healthcare system. The therapies Implantica develops are based on implants, which are inserted into the patient’s body to replace bodily functions and/or treat diseases. Implantica’s most progressed product, RefluxStop ®, represents a strong potential for a paradigm shift in the treatment of GERD, based on excellent clinical evidence. Acid reflux has a significant impact on patient quality of life and, if left untreated, can induce serious complications, including increased risk for esophageal cancer. GERD patients rely today, to a large extent, on PPIs – a drug therapy which calms the symptoms of GERD. Ultimately, with PPI treatment, the side effects are severe, involving a risk of early death (as published by Yan Xie et al. on >150,000 U.S. veterans taking PPI for 10 years1). Reflux of stomach fluid is not prevented by PPIs and the risk for developing serious complications, including esophageal cancer, remains. According to a study by Brusselaers et al. from Karolinska Institute2, 38% of all patients dying from esophageal cancer were PPI users. Alternative surgical procedures available today are often plagued with complications, including affecting the food passageway and causing swallowing difficulties. In addition to RefluxStop®, Implantica has developed two platform technologies: an eHealth platform and a wireless energizing platform as well as a broad, patent-protected product pipeline, two-thirds of which are based on the company’s two platform technologies. Bringing advanced technology and smart medical implants into the body requires enough power to activate a device inside the body long-term, which is the reason why a wireless energising platform has been developed. The eHealth platform is necessary for communicating with and reprogramming implants and adjusting treatment remotely. These platform technologies are covered by a multitude of patents and patent applications. References: (1) Xie Y, Bowe B, Yan Y, Xian H, Li T, Al-Aly Z. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ. 2019;365:l1580. (2) Brusselaers N, Engstrand L, Lagergren J. Maintenance proton pump inhibition therapy and risk of oesophageal cancer. Cancer Epidemiol. 2018;53:172-7. Top ten shareholders as of 30 June 2026 Name Capital (%) Peter Forsell 46.5% Handelsbanken Fonder 9.1% EFG Bank 6.9% UBS 3.6% Avanza Pension 3.0% UBP 2.8% SEB Life 2.1% SIX SIS AG 1.6% Nordea Liv 1.4% Stephan Siegenthaler 1.3%
Page 5
IMP L A NT I CA I NT E R IM R E P O R T Q2-26 5 Financial performance in brief Figures in parentheses within the following section refer to the corresponding period in the preceding year. Net sales During the second quarter, net sales amounted to EUR 717 thousand (433), corresponding to an increase of EUR 284 thousand or 66%. Implantica currently solely markets its lead product, RefluxStop™, exclusively through selected Key Opinion Leaders in Europe. For the first six months, sales amounted to EUR 1,574 thousand (1,178), corresponding to an increase of EUR 396 thousand or 34%. Cost of sales and gross margin Cost of sales during the second quarter amounted to EUR 348 thousand (351). Cost of sales comprises two categories of expenses. The first consists of indirect costs related to the straight-line amortization of capitalized development costs associated with RefluxStop™. The second, Other cost of sales, mainly relates to direct costs for the procurement of goods and services from the Group’s outsourcing partners. In the second quarter, adjusted gross margin, defined as gross margin excluding amortization, amounted to 94% (90%). The cost of sales over the first six months of the year amounted to EUR 712 thousand (681). The adjusted gross margin1, amounted to 94% (94%). Operating expenses and EBIT In the second quarter operating loss (EBIT) amounted to EUR 4,200 thousand (4,525), a decrease of EUR 325 thousand or 7%, compared to the corresponding period last year. Research and development costs amounted to EUR 1,470 thousand (1,385), corresponding to an increase of EUR 85 thousand or 6%. The increase in Research and development costs was primarily driven by the FDA submission. General and administrative costs amounted to EUR 3,099 thousand (3,222), a decrease of EUR 123 thousand or 4% compared to the corresponding period last year. For the first six months of the year, the operating loss (EBIT) amounted to EUR 8,058 thousand (8,698). Where Research and development costs amounted to EUR 3,165 thousand (2,961), corresponding to an increase of EUR 204 thousand or 7% compared to the first six months of 2025. General and administrative costs decreased to EUR 5,755 thousand (6,234), a decrease of EUR 479 thousand or 8%. Financial income and expenses Financial income amounted to EUR 293 thousand (744) during the second quarter. Financial expenses amounted to EUR 79 thousand (1,664) over the quarter driven by foreign exchange losses. For the first six months of the year, Financial income amounted to EUR 377 thousand (610) and Financial expenses totaled EUR 582 thousand (117). Income taxes The Group reported a tax expense of EUR 1 thousand (3) in the second quarter. The tax expense for the quarter is mainly explained by changes in deferred tax assets. For the first six months of the year, the Group reported a tax expense of EUR 4 thousand (7). Net earnings The Group reported a net loss of EUR 3,987 thousand (5,448) for the second quarter, a decrease of EUR 1,461 thousand driven by higher net sales and lower financial expenses. For the first six months of the year, the net loss amounted to EUR 8,267 thousand (8,212), a slight increase of EUR 55 thousand. 1 Adjusted gross profit as a percentage of Net sales. Where Adjusted gross profit is defined as Net sales minus cost of sales, plus amortization of development costs.
Page 6
IMP L A NT I CA I NT E R IM R E P O R T Q2-26 6 Equity and liabilities As of 30 June 2026, the Group’s equity amounted to EUR 75.3 million (92.8) with an equity ratio of 96%, compared to 98% at 30 June 2025. As of 30 June 2026, the Group did not have any interest- bearing debt. Cash flow and liquidity During the second quarter net cash outflow from operating activities amounted to EUR 3,907 thousand (3,919). Net cash outflow from operating activities over the first six months of 2026 amounted to EUR 7,567 thousand (8,444). As of 30 June 2026, Implantica held cash and cash equivalents of EUR 41.7 million. Auditor’s review This report has not been reviewed by the company’s auditors.
Page 7
IMP L A NT I CA I NT E R IM R E P O R T Q2-26 7 Consolidated interim financial statements Condensed consolidated statement of profit or loss Apr to Jun Jan to Jun Jan to Dec in thousands of EUR 2026 2025 2026 2025 2025 Net Sales 717 433 1,574 1,178 2,073 Cost of sales Amortization of capitalized development costs (307) (307) (614) (614) (1,227) Other cost of sales (41) (44) (98) (67) (136) Total cost of sales (348) (351) (712) (681) (1,363) Gross profit 369 82 862 497 710 Impairment of development costs - - - - (1,259) Research and development costs (Note 4) (1,470) (1,385) (3,165) (2,961) (7,354) General and administrative costs (3,099) (3,222) (5,755) (6,234) (12,620) Operating loss (4,200) (4,525) (8,058) (8,698) (20,523) Financial income 293 744 377 610 937 Financial expenses (79) (1,664) (582) (117) (197) Loss before income taxes (3,986) (5,445) (8,263) (8,205) (19,783) Income taxes (1) (3) (4) (7) (32) Loss for the period (3,987) (5,448) (8,267) (8,212) (19,815) Attributable to Owners of Implantica AG (3,966) (5,427) (8,229) (8,136) (19,626) Non-controlling interests (21) (21) (38) (76) (189) Loss for the period (3,987) (5,448) (8,267) (8,212) (19,815) Earnings per share (Note 5) Basic and diluted loss per share Class A (in EUR) (0.06) (0.08) (0.12) (0.12) (0.28) Basic and diluted loss per share Class B (in EUR) (0.00) (0.00) (0.00) (0.00) (0.00)
Page 8
IMP L A NT I CA I NT E R IM R E P O R T Q2-26 8 Condensed consolidated statement of profit or loss and other comprehensive income Apr to Jun Jan to Jun A p r t o Ju n Jan to Dec in thousands of EUR 2026 2025 2026 2025 2025 Loss for the period (3.987) (5,448) (8,267) (8,212) (19,815) Other comprehensive income Remeasurement of net defined benefit liability (28) 56 (50) (9) 110 Total items that will not be reclassified to profit or loss (28) 56 (50) (9) 110 Translation differences (Note 6) (5) 1,204 616 406 629 Total items that may be reclassified subsequently to profit or loss (5) 1,204 616 406 629 Other comprehensive income for the period, net of tax (23) 1,260 566 397 739 Total comprehensive income for the period (4,010) (4,188) (7,701) (7,815) (19,076) Attributable to Owners of Implantica AG (3,991) (4,248) (7,738) (8,072) (19,220) Non-controlling interests 19 60 37 257 144 Total comprehensive income for the period (4,010) (4,188) (7,701) (7,815) (19,076)
Page 9
IMP L A NT I CA I NT E R IM R E P O R T Q2-26 9 Condensed consolidated statement of financial position 30 Jun 31 Dec in thousands of EUR 2026 2025 2025 ASSETS Current assets Cash and cash equivalents (Note 7) 41,733 21,930 19,862 Accounts receivable 1,028 500 666 Other current receivables 2,151 2,296 1,980 Inventories 360 196 305 Current financial assets (Note 7) - 34,383 29,000 Total current assets 45,272 59,305 51,813 Non-current assets Property, plant and equipment 183 253 217 Right-of-use assets (Note 9) 187 - 207 Intangible assets (Note 4) 32,135 34,659 32,768 Deferred tax assets 895 966 895 Total non-current assets 33,400 35,878 34,087 Total assets 78,672 95,183 85,900 LIABILITIES AND EQUITY Current liabilities Trade payable 242 11 34 Financial liabilities 100 - 87 Financial liabilities due to ultimate main shareholder 1 1 1 Other current liabilities 2,739 2,034 2,788 Total current liabilities 3,082 2,046 2,910 Non-current liabilities Financial liabilities 90 - 122 Pension liability 243 363 274 Total non-current liabilities 333 363 396 Total liabilities 3,415 2,409 3,306 Equity Share capital (Note 6) 129,712 129,351 129,596 Capital reserves 370,550 370,548 370,550 Treasury share reserve (Note 6) - (47) - Translation differences (Note 6) 15,015 14,251 14,474 Retained earnings (437,623) (419,008) (429,592) Total equity attributable to owners of Implantica AG 77,654 95,095 85,028 Non-controlling interests (2,397) (2,321) (2,434) Total equity 75,257 92,774 82,594 Total liabilities and equity 78,672 95,183 85,900
Page 10
IMP L A NT I CA I NT E R IM R E P O R T Q2-26 10 Condensed consolidated statement of cash flows Apr to Jun Jan to Jun Jan to Dec in thousands of EUR 2026 2025 2026 2025 2025 Loss for the period (3,987) (5,448) (8,267) (8,212) (19,815) Adjustments for Depreciation, amortization and impairment 359 408 720 816 2,790 Financial income (293) (744) (377) (610) (937) Financial expenses 79 1,664 582 117 197 Income taxes 1 3 4 7 32 Share-based compensation 183 398 364 431 1,507 Other financial result (7) (4) (13) (11) (23) Change in pension liabilities 9 11 17 21 48 Other non-cash items (21) 20 (16) - 49 Changes in net working capital Decrease / (increase) accounts receivable (55) 320 (362) 89 (77) Decrease / (increase) other current receivables (231) (354) (323) (184) (77) Decrease / (increase) inventories (96) 10 (55) 30 (79) (Decrease) / increase trade payable 215 (29) 208 (286) (263) (Decrease) / increase other current liabilities (63) (174) (49) (652) 86 Net cash outflow from operating activities (3,907) (3,919) (7,567) (8,444) (16,562) Cash flows from investing activities Purchase of property, plant and equipment - (34) - (59) (64) Investment in intangible assets (Note 4) - - - (8) (8) Investment in fixed term deposits (Note 7) - - - (34,220) (63,220) Redemption of fixed term deposits (Note 7) - - 29,000 - 34,374 Interest received 174 126 476 136 676 Net cash inflow/(outflow) from investing activities 174 92 29,476 (34,151) (28,242) Cash flows from financing activities Treasury shares disposal - - - - 5 Payment of lease liabilities (23) (74) (45) (146) (184) Interest paid (2) (3) (4) (7) (12) Net cash outflow from financing activities (25) (77) (49) (153) (191) Net increase/(decrease) in cash and cash equivalents (3,758) (3,904) 21,860 (42,748) (44,995) Effect of exchange rate fluctuations on cash held (33) 81 11 126 305 Cash and cash equivalents at beginning of period 45,524 25,753 19,862 64,552 64,552 Cash and cash equivalents at end of period 41,733 21,930 41,733 21,930 19,862
Page 11
IMP L A NT I CA I NT E R IM R E P O R T Q2-26 11 Condensed consolidated statement of changes in equity Jan to Jun 2026 in thousands of EUR Share capital Capital reserves Treasury share reserve Translation differences Retained earnings Total Non- controlling interests Total equity Balance at 31 December 2025 129,596 370,550 - 14,474 (429,592) 85,028 (2,434) 82,594 Loss for the period - - - - (8,229) (8,229) (38) (8,267) Other comprehensive income (net) - - - 541 (50) 491 75 566 Total comprehensive income (net) - - - 541 (8,279) (7,738) 37 (7,701) Share-based compensation 116 - - - 248 364 - 364 Total transactions with shareholders 116 - - - 248 364 - 364 Balance at 30 June 2026 129,712 370,550 - 15,015 (437,623) 77,654 (2,397) 75,257 Jan to Jun 2025 in thousands of EUR Share capital Capital reserves Treasury share reserve Translation differences Retained earnings Total Non- controlling interests Total equity Balance at 31 December 2024 129,351 370,548 (71) 14,178 (411,270) 102,736 (2,578) 100,158 Loss for the period - - - - (8,136) (8,136) (76) (8,212) Other comprehensive income (net) - - - 73 (9) 64 333 397 Total comprehensive income (net) - - - 73 (8,145) (8,072) 257 (7,815) Share-based compensation - - 24 - 407 431 - 431 Total transactions with shareholders - - 24 - 407 431 - 431 Balance at 30 June 2025 129,351 370,548 (47) 14,251 (419,008) 95,095 (2,321) 92,774
Page 12
IMP L A NT I CA I NT E R IM R E P O R T Q2-26 12 Notes NOTE 1 General information Implantica AG (the ‘Company’) is domiciled at Austrasse 15, 9490 Vaduz, Liechtenstein. These condensed consolidated interim financial statements (‘interim financial statements’) as at and for the six month ended 30 June 2026 comprise the Company and its subsidiaries (together referred to as the ‘Group’). The Group is primarily involved in the research and distribution of medical implants. Implantica AG was admitted to trading on the Nasdaq First North Premier Growth Market in Stockholm in September 2020. Implantica AG is ultimately controlled by the Implantica Founder, Dr. Peter Forsell. These interim financial statements were authorized for issue by the Company’s Board of Directors on 20 August 2026. As of this date, no material events after the reporting date have occurred. NOTE 2 Summary of significant accounting policies Basis of preparation These interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting and should be read in conjunction with the Group’s consolidated financial statements as at and for the year ended 31 December 2025 (‘last financial statements’). These interim financial statements do not include all of the information required for a complete set of financial statements prepared in accordance with IFRS Accounting Standards. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance since the last financial statements. For the preparation of these financial statements the historical cost basis except for all those assets and liabilities measured at fair value has been applied. All amounts are presented in EUR, and are rounded to the nearest thousand of EUR with the consequence that the rounded amounts may not add to the rounded total in all cases. All ratios and variances are calculated using the underlying amounts rather than the rounded amounts. Critical accounting estimates and judgements In preparing these interim financial statements, management has made judgements and estimates that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates. The significant judgements made by management in applying the Group’s accounting policies and the key sources of estimation uncertainty were the same as those described in the last annual financial statements. NOTE 3 General accounting policies The accounting policies applied in these interim financial statements are the same as those applied in the Group’s consolidated financial statements as at and for the year ended 31 December 2025. There were no new standards or amendments to existing standards that have a material effect on the Group’s interim financial statements. Accounting standards issued but not yet effective A number of new accounting standards and amendments to accounting standards are effective for annual periods beginning after 1 January 2026 and earlier application is permitted. The Group has not early adopted any of the forthcoming new or amended accounting standards in preparing these condensed consolidated interim financial statements. NOTE 4 Intangible assets Jan to Jun in thousands of EUR 2026 2025 Net carrying amount at 1 January 32,768 35,292 Additions Jan to Mar - - Additions Apr to Jun - - Amortization Jan to Mar (316) (316) Amortization Apr to Jun (316) (316) Translation differences (1) (1) Net carrying amount at 30 June 32,135 34,659 For the second quarter research and development costs in the amount of EUR 1,470 thousand were recognized in profit or loss since the conditions for capitalization as intangible assets for these costs are not met (YTD: EUR 3,165 thousand).
Page 13
IMP L A NT I CA I NT E R IM R E P O R T Q2-26 13 NOTE 5 Earnings per share Apr to Jun Jan to Jun Jan to Dec in thousands of EUR 2026 2025 2026 2025 2025 Loss for the period attributable to owners of Implantica AG (3,966) (5,427) (8,229) (8,136) (19,626) Weighted average % of Class A share capital in total share capital 83.8% 83.8% 83.8% 83.8% 83.8% Weighted average % of Class B share capital in total share capital 16.2% 16.2% 16.2% 16.2% 16.2% Class A shares Loss for the period attributable to Class A shareholders (3,325) (4,548) (6,899) (6,818) (16,448) Weighted average number of outstanding Class A shares 58,352,574 58,188,585 58,341,864 58,183,946 58,226,758 Basic and diluted (loss) per share Class A (in EUR) (0.06) (0.08) (0.12) (0.12) (0.28) Class B shares Loss for the period attributable to Class B shareholders (641) (879) (1,330) (1,318) (3,178) Weighted average number of Class B shares 1,125,000,000 1,125,000,000 1,125,000,000 1,125,000,000 1,125,000,000 Basic and diluted (loss) per share Class B (in EUR) (0.00) (0.00) (0.00) (0.00) (0.00) Earnings per category of shares Earnings per class of shares (Note 6) are calculated on the basis of the net loss attributable to the shareholders of Implantica AG based on their portion of the share capital and the average number of outstanding shares (i.e. excluding treasury shares). Anti-dilutive effect of potential outstanding shares The impact of share-based compensation arrangements was not considered in the diluted earnings per share calculation for Class A shares for the periods presented because due to the net loss for these periods their effect would have been anti-dilutive. NOTE 6 Equity Share capital The fully paid in share capital of the Group amounts to CHF 139,259 thousand (EUR 129,712 thousand) and is divided into 58,379,700 registered shares with a nominal value of CHF 2.00 each (Class A) and 1,125,000,000 with a nominal value of CHF 0.02 each (Class B). During the second quarter 2026 the Group delivered 40,467 Class A shares to employees as part of existing share-based payment commitments (YTD: 53,232). Translation differences During the second quarter the EUR/CHF exchange rate decreased slightly from 1.088 to 1.084. As a result, the group recognized a total loss of EUR 5 thousand for the quarter in other comprehensive income related to the translation of financial statements of foreign operations and net investments in foreign operations (YTD: EUR 616 thousand). NOTE 7 Cash and cash equivalents and financial assets Following the redemption in January 2026 of the EUR 29,000 thousand term deposit held at 31 December 2025 as a current financial asset, the Group entered into a new term deposit agreement with the same Swiss bank for EUR 29,000 thousand, maturing on 30 April 2026, at an interest rate of 2.20%. As the term of this new deposit does not exceed three months, it is classified as cash and cash equivalents, whereas the previous deposit was classified as a current financial asset. Subsequently, in May 2026, the Group entered into two new term deposit agreements with the same Swiss bank for EUR 30,000 thousand and SEK25,000 thousand, at interest rates of 2.32% and 1.58% respectively. Both of these deposits mature on 4 August 2026, and thus do not exceed the period of three months to maturity.
Page 14
14 Other Telephone conference Implantica will hold a teleconference on 21 August 2026 at 15:00 (CEST) with Peter Forsell (CEO), Andreas Öhrnberg (CFO), and Nicole Pehrsson (Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference: Webcast If you wish to participate via webcast, please use the following link: https://implantica.events.inderes.com/q2-report-2026 Dial-in If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the conference. https://events.inderes.com/implantica/q2-report- 2026/dial-in Financial calendar 19 November 2026 Interim Report Q3 2026 Listing Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm. The company is traded under the ticker symbol IMP A SDB and ISIN code SE0014855029. Disclaimer statement Some statements herein are forward-looking, and the actual outcome could be materially different. In addition to the factors explicitly commented upon, the actual outcome could be materially affected by other factors, for example: the impact of undesired side effects related to existing or future products, failures in handling of the quality system, obstacles in obtaining CE and FDA approvals and re-certifications, products may fail to become subject to insurance and reimbursement policies and risk not gaining widespread acceptance, clinical trials may prove to be unsuccessful and the impact of competing products. Contacts Nicole Pehrsson, Chief Corporate Affairs Officer Telephone: +41 (0)43 505 20 57 E-mail: nicole.pehrsson@implantica.com Peter Forsell, CEO E-mail: peter.forsell@implantica.com Andreas Öhrnberg, CFO E-mail: andreas.oehrnberg@implantica.com Implantica AG Austrasse 15 9490 Vaduz Liechtenstein www.implantica.com IMPLANTI CA I NTERI M REP ORT Q 2-26